DK2456786T4 - Lentivirusvektorer, der er pseudotypebestemt med et kappeglycoprotein fra sindbis-virus - Google Patents

Lentivirusvektorer, der er pseudotypebestemt med et kappeglycoprotein fra sindbis-virus Download PDF

Info

Publication number
DK2456786T4
DK2456786T4 DK10737715.2T DK10737715T DK2456786T4 DK 2456786 T4 DK2456786 T4 DK 2456786T4 DK 10737715 T DK10737715 T DK 10737715T DK 2456786 T4 DK2456786 T4 DK 2456786T4
Authority
DK
Denmark
Prior art keywords
ala
thr
ser
val
leu
Prior art date
Application number
DK10737715.2T
Other languages
English (en)
Other versions
DK2456786T3 (da
Inventor
James M Allen
Hoeven Neal S Van
jin zhong Li
Derek D Sloan
Thomas W Dubensky Jr
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2456786(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Application granted granted Critical
Publication of DK2456786T3 publication Critical patent/DK2456786T3/da
Publication of DK2456786T4 publication Critical patent/DK2456786T4/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50Colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001156Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188NY-ESO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001191Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001192Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194Prostate specific antigen [PSA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145Special targeting system for viral vectors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)

Claims (23)

1. Lentivirusvektorpartikel, der omfatter: (a) en kappe, der omfatter (i) et Sindbis-virus E2-glycoprotein ifølge SEQ ID NO: 1, hvori 160X er fraværende eller er en anden aminosyre end glutaminsyre, eller en variant af SEQ ID NO: 1 med mindst 80 % identitet med SEQ ID NO: 1, og hvori 160X er fraværende eller er en anden aminosyre end glutaminsyre, der er i stand til at inficere dendritceller; hvor E2 ikke er en del af et fusionsprotein med Sindbis-virus E3; og (b) et lentivirusvektorgenom, der omfatter en eller flere sekvenser af interesse.
2. Lentivirusvektorpartikel ifølge krav 1, hvor 160X er fraværende eller er glycin, alanin, valin, leucin eller isoleucin, såsom udvalgt blandt glycin, valin, leucin eller isoleucin.
3. Lentivirusvektorpartikel ifølge krav 1 eller 2, hvor E2-glycoproteinvarianten har mindst én aminosyre, der er ændret, så dens positive nettoladning er reduceret.
4. Lentivirusvektorpartikel ifølge krav 3, hvor den mindst ene aminosyre, der er ændret for at reducere den positive nettoladning, er udvalgt blandt lysin 70, lysin 76 eller lysin 159 i SEQ ID NO: 1, og fortrinsvis hvor substituenterne er udvalgt uafhængigt blandt glutaminsyre eller asparaginsyre.
5. Lentivirusvektorpartikel ifølge krav 1, hvor E2- variantsekvensen er aminosyreresterne 66 til 488 af SEQ ID NO: 3, aminosyreresterne 66 til 488 af SEQ ID NO: 4 eller aminosyreresterne 66 til 486 af SEQ ID NO: 5; (variant 1, 2 og 3) .
6. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-5, som er en variant, hvori sekvensen af resterne 71-75 af SEQ ID NO: 1 er uændret eller har en eller to substitutioner, som ikke påvirker variantens evne til at inficere DC'er, men ikke ændrer antallet af aminosyrer i dette område.
7. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-6, hvor sekvensen af interesse udtrykker et produkt, som er et antigen fra et sygdomsforårsagende middel eller en angreben celle.
8. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-6, hvor sekvensen af interesse koder for et tumorspecifikt antigen, eventuelt NY-ESO-1, MAGE, MART-1/Melan-A, BAGE, RAGE, et antigen fra en melanocyt-melanom-cellelinje, såsom gplOO, gp75, mda-7, tyrosinase eller tyrosinase-relateret protein; renalcellekarcinom-antigen, 5T4, SM22-alfa, carboanhydrase I, carboanhydrase IX (også kendt som G250) , hypoxia-inducerbare faktorer (valgfrit HIF-l-alfa eller HIF-2-alfa) , VEGF eller prostataspecifikt membranantigen (PSMA), prostataspecifikt antigen (PSA), prostatasyrephosphater, seks-transmembrant epitelialt antigen fra prostata (STEAP), NKX3.1, epitopproteiner/peptider, der er afledt fra gener, der er muteret i tumorceller, eller gener, der transkriberes ved andre niveauer i tumor sammenlignet med normale celler, såsom telomerase-enzym, survivin, mesothelin, muteret ras, bcr/abl-omlejring, Her2/neu, muteret eller vildtype-p53, cytochrom P450-1B1, anormalt udtrykte intronsekvenser, såsom N-acetylglucosaminyltransferase-V; klonale omlejringer af immunoglobulingener, der frembringer unikke idiotyper i myelom eller B-cellelymfomer; epitopproteiner/peptider, der stammer fra onkovirale processer, såsom humane papillomavirusproteiner E6 eller E7; eller ikke-muterede onkoføtale proteiner med en tumorselektiv ekspression, såsom karcinoembryonisk antigen eller alfa-fetoprotein.
9. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-7, hvor sekvensen af interesse koder for et virusafledt antigen, såsom et HIV- eller SIV-antigen, adenovirus-polypeptid, alfavirus-polypeptider, calicivirus- polypeptider, f.eks. et calicivirus-capsidantigen, coronavirus-polypeptider, distempervirus-polypeptid, Ebolavirus-polypeptid, enterovirus-polypeptid, flavivirus- polypeptid, hepatitisvirus (AE)-polypeptid, f.eks. et hepatitis B-kerne- eller overfladeantigen, eller hepatitis C-virus El- eller E2-glycoproteiner, kerne- eller ikke-strukturproteiner, herpesvirus-polypeptid, f.eks. et herpes simplex virus- eller varicella zoster virus- glycoprotein, immundefektvirus-polypeptid, f.eks. human immundefektvirus-kappe eller protease, infektiøs peritonitisvirus-polypeptid, influenzavirus-polypeptid, f.eks. et influenza A-hemagglutinin, neuraminidase; eller nukleoprotein, leukæmivirus-polypeptid, Marburg-virus- polypeptid, orthomyxovirus-polypeptid, papillomavirus- polypeptid, parainfluenzavirus-polypeptid, f.eks. hemagglutinin/neuraminidase, paramyxovirus-polypeptid, parvovirus-polypeptid, pestivirus-polypeptid, picornavirus-polypeptid, f.eks. et polioviruscapsid-polypeptid, poxvirus-polypeptid, f.eks. et vacciniavirus-polypeptid, rabiesvirus-polypeptid, f.eks. et rabiesvirus-glycoprotein G, reovirus-polypeptid, retrovirus-polypeptid eller rotavirus-polypeptid.
10. Sammensætning, der omfatter en lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-9, hvor sammensætningen har en IU på mindst 105/ml.
11. Lentivirusvektorpakningssystem til frembringelse af en pseudotype lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10, der omfatter: (i) et første nukleinsyremolekyle, der koder for Sindbis-virus E2-glycoproteinet ifølge krav 1 (a)(i), og; (ii) et andet nukleinsyremolekyle, der koder for gag- og polproteiner, (iii) et tredje nukleinsyremolekyle, der koder for rev; (iv) et lentivirusvektorgenom, der omfatter en sekvens af interesse; og (v) en pakningscelle.
12. Lentivirusvektorpakningssystem ifølge krav 11, hvor: (a) pol-proteinet har en ikke-funktionel integrase; og/eller (b) pol-proteinet har en ikke-funktionel integrase med en D64V-mutation; og/eller (c) lentivirusvektorgenomet er et ikke-integrerende lentivirusgenom; og/eller (d) pakningscellen er stabilt transformeret med (ii) og (iii); og/eller (e) pakningscellen er transficeret med (i) og (iv).
13. Isoleret nukleinsyremolekyle, der omfatter en nukleotidsekvens, der koder for E2-glycoproteinet eller varianten ifølge krav 1 (a) (i) eller et hvilket som helst af kravene 2-9.
14. Nukleinsyremolekyle ifølge krav 13, hvor proteinet er et Sindbis E3/E2/6K/El-polyprotein, der er processeret, således at E2-proteinet ikke er en del af et fusionsprotein med E3, når det inkorporeres i en viruskappe.
15. Nukleinsyremolekyle ifølge krav 14, hvor E3-sekvensen svarer til (a) resterne 1-65 af SEQ ID NO: 20 eller (b) en variant deraf, der har mindst 80 % sekvensidentitet med resterne 1-65 af SEQ ID NO: 20, hvor resterne 62-65 er RSKR (SEQ ID NO: 27), og varianten er i stand til at blive inkorporeret i en pseudotype-viruskappe.
16. Fremgangsmåde til fremstilling af en lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10, som omfatter dyrkning af lentivirusvektorpakningssystemet ifølge krav 11.
17. Lentiviruspartikel ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10, hvor lentivirusvektorgenomet (a) har en inaktiveret eller selv-inaktiverende 3'-LTR (long terminal repeat); og/eller (b) omfatter et U3-element, der mangler mindst det ene af: (i) en enhancersekvens; (ii) en TATA-box; (i i i) et Spl-sted; (iv) et NK-kappa B-sted; og (v) et polypurin-spor (PPT) ; og/eller (c) omfatter nukleotidsekvensen ifølge SEQ ID NO: 21, 22 eller 23; og/eller, (d) omfatter en nukleotidsekvens, der koder for en modningsfaktor/stimulatorisk faktor fra en dendritcelle.
18. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10 til anvendelse i en fremgangsmåde til behandling af et menneske eller et dyr, der eventuelt omfatter fremføring af lentivirusvektorpartikler til dendritceller ex vivo.
19. Lentivirusvektorpartikel ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10 til anvendelse til inducering af en antigenspecifik immunrespons, eventuelt en humoral respons og/eller cellular respons.
20. Terapeutisk eller profylaktisk vaccine, der omfatter lentivirusvektorpartikler ifølge et hvilket som helst af kravene 1-9 eller sammensætning ifølge krav 10 og et farmaceutisk acceptabelt excipiens.
21. Terapeutisk eller profylaktisk vaccine ifølge krav 20, der yderligere omfatter en adjuvans.
22. Terapeutisk eller profylaktisk vaccine ifølge krav 21, hvor adjuvansen er en adjuvans med formel (I):
(i) hvor Δ1 og A2 er udvalgt uafhængigt fra gruppen, der består af hydrogen, phosphat og phosphatsalte, og delene R1, R2, R3, R4, R5 og R6 er udvalgt uafhængigt fra gruppen af hydrocarbyl med 3 til 23 carboner som vist ved C3-C23.
23. Terapeutisk eller profylaktisk vaccine ifølge krav 22, hvor (a) A1 er phosphat eller et phosphatsalt, og A2 er hydrogen, og (b) (i) R1, R3, R5 og R6 er Cn-C2o-alkyl, og R2 og R4 er C12-C20- hydrocarbyl; eller (ii) R1, R3, R5 og R6 er Cn-alkyl, og R2 og R4 er C13- hydrocarbyl; eller (iii) R1, R3, R° og R6 er undecyl, og R2 og R4 er tridecyl.
DK10737715.2T 2009-07-24 2010-07-22 Lentivirusvektorer, der er pseudotypebestemt med et kappeglycoprotein fra sindbis-virus DK2456786T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Publications (2)

Publication Number Publication Date
DK2456786T3 DK2456786T3 (da) 2014-03-24
DK2456786T4 true DK2456786T4 (da) 2017-08-07

Family

ID=42727669

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13194273.2T DK2770061T3 (da) 2009-07-24 2010-07-22 Ikke-integrerende lentivirusvektorer
DK10737715.2T DK2456786T4 (da) 2009-07-24 2010-07-22 Lentivirusvektorer, der er pseudotypebestemt med et kappeglycoprotein fra sindbis-virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13194273.2T DK2770061T3 (da) 2009-07-24 2010-07-22 Ikke-integrerende lentivirusvektorer

Country Status (28)

Country Link
US (3) US20110064763A1 (da)
EP (2) EP2770061B1 (da)
JP (4) JP2013500015A (da)
KR (1) KR101790187B1 (da)
CN (1) CN102482329B (da)
AU (1) AU2010276194B2 (da)
BR (1) BR112012001653A2 (da)
CA (1) CA2768938C (da)
CY (1) CY1121159T1 (da)
DK (2) DK2770061T3 (da)
EA (1) EA032403B1 (da)
ES (2) ES2455544T5 (da)
HK (1) HK1201557A1 (da)
HR (2) HRP20140327T4 (da)
HU (1) HUE043032T2 (da)
IL (1) IL217679A (da)
LT (1) LT2770061T (da)
ME (1) ME01720B (da)
MX (1) MX2012001075A (da)
NZ (1) NZ597804A (da)
PL (2) PL2456786T5 (da)
PT (2) PT2456786E (da)
RS (2) RS58042B1 (da)
SG (1) SG177744A1 (da)
SI (2) SI2770061T1 (da)
SM (1) SMT201400041B (da)
TR (1) TR201819229T4 (da)
WO (1) WO2011011584A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949208B1 (en) * 2009-07-15 2017-11-15 Calimmune Inc. Dual vector for inhibition of human immunodeficiency virus
CA2826920A1 (en) * 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
EP2844746A4 (en) 2012-03-26 2016-07-20 Univ California LENTIVIRUS PSEUDOTYPED WITH NIPAH VIRUS ENVELOPE AND METHODS OF USE
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
CN104583231B (zh) 2012-03-30 2021-02-26 免疫设计公司 具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
WO2014109728A1 (en) * 2013-01-11 2014-07-17 The Scripps Research Institute Methods and compositions for enchancing transduction efficiency of retroviral vectors
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
PL3116900T3 (pl) 2014-03-09 2021-03-08 The Trustees Of The University Of Pennsylvania Kompozycje użyteczne w leczeniu niedoboru transkarbamylazy ornitynowej (otc)
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
EP3247409B1 (en) 2015-01-21 2020-11-04 Cornell University Viral vectors for prophylaxis and therapy of hemoglobinopathies
CN107429232B (zh) * 2015-01-26 2023-01-03 菲特治疗公司 免疫调节性提高的细胞及其使用和生产方法
EP3270958A4 (en) * 2015-03-18 2018-11-14 Omnicyte Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
DK3283658T3 (da) 2015-05-18 2020-05-18 Calimmune Inc Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
JP2018532386A (ja) 2015-09-09 2018-11-08 イミューン デザイン コーポレイション Ny−eso−1特異的tcrおよびそれらの使用方法
EP3738973A1 (en) 2015-11-09 2020-11-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
WO2017083356A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
MX2018010061A (es) * 2016-02-23 2019-07-04 Immune Design Corp Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas.
JP2019510488A (ja) * 2016-03-04 2019-04-18 ニューヨーク・ユニバーシティ 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
NZ746934A (en) 2016-04-15 2023-11-24 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN110352245A (zh) 2016-10-20 2019-10-18 高山免疫科学股份有限公司 可分泌变体免疫调节蛋白和工程化细胞疗法
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
DK3596116T5 (da) 2017-03-16 2024-09-02 Alpine Immune Sciences Inc Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018208728A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering, Inc. Compositions for facilitating membrane fusion and uses thereof
US20200283500A1 (en) 2017-10-18 2020-09-10 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20220010334A1 (en) * 2018-11-23 2022-01-13 Vira Therapeutics Gmbh Vsv chimeric vectors
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
WO2020252305A1 (en) 2019-06-14 2020-12-17 The J. David Gladstone Institutes, A Testamentary Trust Establishe Under The Will Of J. David Gladstone Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
WO2021022308A2 (en) * 2019-08-01 2021-02-04 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Constructs of CD8-specific antibodies and preparations thereof
WO2023196442A1 (en) * 2022-04-05 2023-10-12 Bio-Rad Laboratories, Inc. Analysis of viral particles by digital assay
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
CA1339684C (en) 1988-05-17 1998-02-24 Peter H. Quail Plant ubquitin promoter system
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (da) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
EP0840797B1 (en) 1995-07-25 2014-09-03 Crucell Holland B.V. Methods and means for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
ATE435297T1 (de) * 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
CA2366054A1 (en) * 1999-03-16 2000-09-21 Wayne A. Marasco Lentiviral vector system for high quantity screening
EP1175497B1 (en) 1999-04-14 2010-04-07 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
EP1214437A1 (en) 1999-08-27 2002-06-19 The Regents of the University of California Use of lentiviral vectors for antigen presentation in dendritic cells
EP1221968B1 (en) 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
EP1368058A4 (en) * 2001-03-02 2005-01-12 Merck & Co Inc VIRAL RAPPORTEUR PARTICLES
JPWO2002101057A1 (ja) * 2001-06-08 2004-09-24 株式会社ディナベック研究所 Vsv−gシュードタイプ化サル免疫不全ウイルスベクターを用いた霊長類胚性幹細胞への遺伝子導入
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
WO2003022228A2 (en) 2001-09-13 2003-03-20 California Institute Of Technology Method for producing transgenic birds and fish
EP1424896B1 (en) 2001-09-13 2016-08-03 California Institute Of Technology Method for expression of small rna molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
WO2003041763A2 (en) 2001-11-14 2003-05-22 Medical Instill Technologies, Inc. Intradermal delivery device and method
KR101020724B1 (ko) 2002-02-04 2011-03-09 벡톤 디킨슨 앤드 컴퍼니 피부를 통하여 물질을 전달하거나 회수하는 장치 및, 방법
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
ES2326217T3 (es) * 2002-04-26 2009-10-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Glicoproteinas quimericas mejoradas y vectores lentivirales pseudotipados.
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
JP5145492B2 (ja) 2002-08-16 2013-02-20 独立行政法人科学技術振興機構 組換えbcgワクチン
AU2003297474A1 (en) 2002-12-18 2004-07-14 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
WO2004067710A2 (en) 2003-01-21 2004-08-12 Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US20050214318A1 (en) 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US7429481B2 (en) * 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
ES2459192T3 (es) 2006-07-21 2014-05-08 California Institute Of Technology Introducción selectiva de genes para la vacunación con células dendríticas
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
HUE036103T2 (hu) * 2007-12-11 2018-06-28 Univ North Carolina Chapel Hill Polipurin szakaszon módosított retrovirális vektorok

Also Published As

Publication number Publication date
MX2012001075A (es) 2012-05-22
US8187872B2 (en) 2012-05-29
EP2770061A1 (en) 2014-08-27
ES2455544T3 (es) 2014-04-16
PT2770061T (pt) 2018-12-24
TR201819229T4 (tr) 2019-01-21
AU2010276194A1 (en) 2011-11-24
WO2011011584A1 (en) 2011-01-27
KR20120068838A (ko) 2012-06-27
NZ597804A (en) 2013-10-25
CY1121159T1 (el) 2020-05-29
RS53257B2 (sr) 2018-06-29
JP2017060535A (ja) 2017-03-30
PL2770061T3 (pl) 2019-02-28
SI2770061T1 (sl) 2019-02-28
JP2013500015A (ja) 2013-01-07
CN102482329B (zh) 2017-11-14
HK1201557A1 (en) 2015-09-04
ME01720B (me) 2014-09-20
US20160076055A1 (en) 2016-03-17
EP2456786B1 (en) 2014-01-08
BR112012001653A2 (pt) 2016-11-08
CN102482329A (zh) 2012-05-30
DK2456786T3 (da) 2014-03-24
HRP20140327T1 (hr) 2014-05-09
US20110064763A1 (en) 2011-03-17
EP2456786A1 (en) 2012-05-30
CA2768938C (en) 2019-05-14
SI2456786T1 (sl) 2014-05-30
SI2456786T2 (sl) 2017-08-31
CA2768938A1 (en) 2011-01-27
ES2702274T3 (es) 2019-02-28
PT2456786E (pt) 2014-03-25
SG177744A1 (en) 2012-02-28
ES2455544T5 (es) 2017-08-16
EP2770061B1 (en) 2018-10-24
RS58042B1 (sr) 2019-02-28
DK2770061T3 (da) 2019-01-07
JP2015109853A (ja) 2015-06-18
KR101790187B1 (ko) 2017-10-25
JP2018198616A (ja) 2018-12-20
HRP20181996T1 (hr) 2019-03-22
JP6701280B2 (ja) 2020-05-27
EA201270191A1 (ru) 2012-12-28
US20120039932A1 (en) 2012-02-16
IL217679A (en) 2016-09-29
RS53257B (en) 2014-08-29
AU2010276194B2 (en) 2012-02-02
JP6170952B2 (ja) 2017-07-26
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
PL2456786T3 (pl) 2014-06-30
HRP20140327T4 (hr) 2017-11-03
HUE043032T2 (hu) 2019-07-29
EA032403B1 (ru) 2019-05-31
PL2456786T5 (pl) 2017-10-31
EP2456786B2 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
DK2456786T4 (da) Lentivirusvektorer, der er pseudotypebestemt med et kappeglycoprotein fra sindbis-virus
US10993999B2 (en) Materials and methods for producing improved lentiviral vector particles
US20160340692A1 (en) Targeted gene delivery for dendritic cell vaccination
US8323662B1 (en) Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US20220054627A1 (en) Retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
US10391157B2 (en) Materials and methods for producing improved lentiviral vector particles